Challenges of glucose control in ckd
-
Upload
drk-sampath-kumar -
Category
Health & Medicine
-
view
182 -
download
2
description
Transcript of Challenges of glucose control in ckd
Diabetes and KidneyDiabetes and Kidney
Dr.SampathkumarMD,DNB,DM,FRCP
MMHRC
1
2 sides of the coin 2 sides of the coin
2
ALL patients with Diabetes and ALL patients with Diabetes and Proteinuria/Renal failure have Proteinuria/Renal failure have
diabetic renal disease .diabetic renal disease .You may be wrong 50% of the
times !
3
Common Pitfall
Indications for Renal Biopsy Indications for Renal Biopsy
4
Diabetic N along with Infection Diabetic N along with Infection related GN related GN
Endocap. Prolif to 100% crescentsEndocap. Prolif to 100% crescents
Progressive grades of CKDProgressive grades of CKD
7
Filtration Pressure +15 mm Hg Filtration Pressure +15 mm Hg
8
Diabetic glomerular diseaseDiabetic glomerular diseaseFlitration Pressure +35Flitration Pressure +35
9
80 mm
Renal and cv risk increases once Renal and cv risk increases once microalbuminuria crosses 6 mg/gmicroalbuminuria crosses 6 mg/g
Albuminuria Renal risk CV event
0-10 1 1
10-20 2.34 1.9
20-30 12.4 9.8
10
New classification of albumin New classification of albumin excretionexcretion
11
12
13
Traditional Vs Novel Traditional Vs Novel
14
Non Proteinuric nephropathyNon Proteinuric nephropathy
15
16
CKD
17
This patient develops KWD within 5 years though his Hb A1 c was 6.5 %
Insulin dynamics in CKDInsulin dynamics in CKD
18
19
20
Insulin half life in CKDInsulin half life in CKD
21
23
24
Use of OHAs in CKDUse of OHAs in CKD
25
Metformin Controversy Metformin Controversy in CKD….in CKD….
26
Pharmacokinetics of MetforminPharmacokinetics of Metformin
27
MALA- Metformin Associated MALA- Metformin Associated Lactic Acidosis Lactic Acidosis • Decreased Utilisation vs hepatic dysfn
ANAEROBIC GLYCOLYSIS
SHOCK STATES
LIVER DYSFNTYPE B
METFORMIN
•2-10 per 100,000 patients receiving metformin /year•MALA accounts for 0.1-1% total patients admitted to ICU•Mortality is high – 30-50%
Balance
2 sites where Metformin acts2 sites where Metformin acts
29
Hypotension rather than Hypotension rather than metformin level which metformin level which determined Lactate accumulationdetermined Lactate accumulation
30
Conclusion from this study
31
SFU in CKDSFU in CKD
• Depends on Renal or Hepatic metabolism
• Depends also on whether metabolites have hypoglycemic effects
32
33
34
35
36
37
Drug exposure(AUC) in renal impairment compared to patients Drug exposure(AUC) in renal impairment compared to patients with normal renal functionwith normal renal function
Drug Mild RI Moderate RI Severe RI Hemodialysis
Metformin NA NA NA NA
GlibenclamideM1+M2
NA NA -45% NA
GlimepirideM2
NA -55%+100%
-55%+400%
NA
Repaglinide NA +19% +32% +32%
Pioglitazone NA -17% to -43% 17% to -43% NA
Sitagliptin +61% +126% +277% +350%
Vildagliptin +40% +71% +100% NA
Saxagliptin(Active metabolite)
+16%+67%
+41%+192%
+108%+347%
NANA
Alogliptin +70% +110% +220% +280%
Linagliptin +29% +56% +41% +54%
Exenatide -19% -3% NA +227%
A.J Scheen. Expert Opinion on Drug Metabolism and Toxicology: 2013
Linagliptin in a recent study lowered albuminuria on top of Linagliptin in a recent study lowered albuminuria on top of standard ACEi/ARB therapy in patients with T2DMstandard ACEi/ARB therapy in patients with T2DM
39
Linagliptin significantly lowers albuminuria on top of recommended standard treatment for diabetic nephropathy
1. Inclusion criteria: Stable ACE/ARB background; albuminuria 30−3000 mg/g creatinine; GFR > 30.*Albuminuria-lowering evidence for linagliptin will emerge from MARLINA 1218.89.
**ADA 2012, 953-P
Adjusted mean change in albuminuria(24 weeks)1
24 weeks’ treatmentEffect of linagliptin on albuminuria in humans*
n
95% CI
59
-20%, +23%
168
-42%, -22%
Placebo Linagliptin
-4%
-33%
-29%p < 0.05
Albuminuria:
Early marker for renal damage
Marker for endothelial dysfunction
Cardiovascular risk factor
Lowering of albuminuria is associated with kidney & CV protection
Definitions
Microalbuminuria
UACR ≥ 30 mg/g creatinine < 300 mg/g creatinine
Macroalbuminuria
UACR ≥ 300 mg/g creatinine
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Proven renal safety with potential for additional kidney benefit– Mean GFR remains unchanged after treatment initiation with linagliptin up
to 24 weeks
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Albuminuria Lowering by Linagliptin is independent of the Improvement in Glucose
Linagliptin significantly lowers albuminuria on top of recommended standard treatment for diabetic nephropathy
1. Inclusion criteria: Stable ACE/ARB background; albuminuria 30−3000 mg/g creatinine; GFR > 30.*Albuminuria-lowering evidence for linagliptin will emerge from MARLINA 1218.89.
**ADA 2012, 953-P
Adjusted mean change in albuminuria(24 weeks)1
24 weeks’ treatmentEffect of linagliptin on albuminuria in humans*
n
95% CI
59
-20%, +23%
168
-42%, -22%
Placebo Linagliptin
-4%
-33%
-29%p < 0.05
Albuminuria:
Early marker for renal damage
Marker for endothelial dysfunction
Cardiovascular risk factor
Lowering of albuminuria is associated with kidney & CV protection
Definitions
Microalbuminuria
UACR ≥ 30 mg/g creatinine < 300 mg/g creatinine
Macroalbuminuria
UACR ≥ 300 mg/g creatinine
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Proven renal safety with potential for additional kidney benefit– Mean GFR remains unchanged after treatment initiation with linagliptin up
to 24 weeks
-29% in albuminuria vs placeboafter 24 weeks’ treatment**
Possible mechanism: The reno-
protective effect of linagliptin as
studies in preclinical modelInhibition of podocyte damage and
Inhibition of myofibroblast
transformation
Increased GLP-1 receptor
expression
40
41
Extreme Hyperglycemia in CKDExtreme Hyperglycemia in CKD
42
Case HistoryCase History
• 67 yrs old male in altered sensorium• Type 2 Diabetes, CAD • On OHA for the past 5 y• Fever,Dysuria – 7 d• Pain abdoment -1 d• Altered sensorium – 12 h• On Glimepride, Metformin ,Metoprolol,
Losartan, eplerenone,Asprin,atorvastatin
Phy ExaminationPhy Examination
• Significant volume depletion• FEBRILE -101,RR 19 /PM• BP -100/70• JVP-Collapsed• S1,S2 FAINT, Lung Bases - clear• Abdomen- Left Lumbar area tender • Catheter draining turbid urine• Drowsy, Neck supple,No FND,Plantar –
Flexor Bil
LabLab
• Urine – Pus cells +++, Bacteria ++• Hb – 9.8, TC – 18,300. P 84,L14,E2• B.Sugar- 604, B Urea – 87,S.Creat-2.3• Na -147,K – 6.2,Cl – 112, HCO3 – 18.PCO2- 35,pO2 -90• Ketone body – neg• ABG - P H – 7.32
Pyuria Hyperglycemia Azotemia HyperNa,HyperK,Met.Acidosis
3 major grades of insulin deficits 3 major grades of insulin deficits
WHY IS HE NOT WHY IS HE NOT KETONEMICKETONEMIC
Calculated osm
ECF hyperosmolality produces ICF ECF hyperosmolality produces ICF dehydrationdehydration
RF PREVENTS GLYCOSURIA
ICF ECF
Na , GK, P
Urea Water
Ethanol
Insulin lack and hyperosmolality drives K outside
60 kg / 10% Deficit/Na 147 60 kg / 10% Deficit/Na 147
6 / 3L
1 L/I hr
0.45%Sal.
H2O /po
Insulin therapy Insulin therapy
53
Hemodialysis for severe Hemodialysis for severe hyperglycemia in CKDhyperglycemia in CKD
55
Extreme hyperglycemia with ketoacidosis and hyperkalemia in a patient on chronic hemodialysis.Hemodial Int. 2008 Oct ;12 Suppl 2:S43-7.
56
CAPD patientCAPD patient
• Dialysate contains • Glucose in high• Concentration
• Hyperglycemia severe and common
57
Icodextrin use in diabetic patientIcodextrin use in diabetic patient• Icodextrin is
Polymer of Glucose• False high reading of
Blood Glucose if • GDH/PQQ strips
are used • Risk of iatrogenic
hypoglycemia due to misdiagnosis and over reaction
58
Renal Transplantation.Renal Transplantation.
59
Post transplant DiabetesPost transplant Diabetes
• Tacrolimus• Cyclosporine• Steroids• CMV• HCV • Metabolic syndrome
60
45 yrs female , Renal TX in 45 yrs female , Renal TX in MMHRC at 1999.Presents with MMHRC at 1999.Presents with proteinuria , edemaproteinuria , edema
61
Arteriolar hyalinosisArteriolar hyalinosis
62
63
Hypoglycemia Vs Hyperglycemia in Hypoglycemia Vs Hyperglycemia in CKD- Tight rope walk!CKD- Tight rope walk!
If he falls your reputation also falls !!